Inactive Instrument

Analyst Reco. Tandem Diabetes Care Inc Nasdaq

Equities

US8753721047

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45	Apr. 25	MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $40 From $37, Maintains Buy Rating	Apr. 23	MT
Stifel Upgrades Tandem Diabetes Care to Buy From Hold, Adjusts Price Target to $37 From $24	Mar. 26	MT
Citigroup Raises Price Target on Tandem Diabetes Care to $31 From $25, Keeps Neutral Rating	Mar. 15	MT
UBS Raises Tandem Diabetes Care Price Target to $28 From $18, Maintains Neutral Rating	Jan. 22	MT
TD Cowen Raises Tandem Diabetes Care Price Target to $35 From $22, Maintains Outperform Rating	Jan. 18	MT
BofA Securities Cuts Price Target on Tandem Diabetes Care to $18 From $33, Keeps Underperform Rating	23-10-18	MT
Citigroup Cuts Tandem Diabetes Care's Price Target to $23 From $31, Keeps Neutral Rating	23-10-02	MT
Jefferies Adjusts Price Target on Tandem Diabetes Care to $45 From $47, Maintains Buy Rating	23-10-02	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $31 From $33, Maintains Neutral Rating	23-08-21	MT
Baird Trims Price Target on Tandem Diabetes Care to $32 From $33, Maintains Neutral Rating	23-08-21	MT
UBS Adjusts Tandem Diabetes Care Price Target to $32 From $30, Maintains Neutral Rating	23-08-07	MT
Barclays Adjusts Price Target on Tandem Diabetes Care to $62 From $71, Keeps Overweight Rating	23-08-07	MT
Baird Adjusts Price Target on Tandem Diabetes Care to $33 From $38, Maintains Neutral Rating	23-08-04	MT
Citigroup Downgrades Tandem Diabetes Care to Neutral From Buy, Adjusts Price Target to $33 From $45	23-08-04	MT
UBS Adjusts Tandem Diabetes Care Price Target to $30 From $45, Maintains Neutral Rating	23-06-14	MT
Craig Hallum Adjusts Tandem Diabetes Care Price Target to $50 From $74, Maintains Buy Rating	23-06-13	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $45 From $55, Keeps Buy Rating	23-06-05	MT
BofA Securities Downgrades Tandem Diabetes Care to Underperform From Neutral, Adjusts Price Target to $33 From $45	23-05-05	MT
Baird Adjusts Price Target on Tandem Diabetes Care to $38 From $40, Maintains Neutral Rating	23-05-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Tandem Diabetes Care Inc Nasdaq

Equities

US8753721047

Analyst Reco.

Filters